Home  >  Products  >  FLJ11730 Blocking Peptide (100ug)
FLJ11730 Blocking Peptide (100ug)

FLJ11730 Blocking Peptide (100ug)


Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-FLJ11730 antibody (Catalogue #: ARP33354_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Presku: AAP33354
Size: 100 ug
Weight: 23kDa
Gene: 64769
Format: Lyophilized powder
Target: The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognized by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.